O’RIGHT
18.11.2020 10:02:09 CET | Business Wire | Press release
As the novel coronavirus spreads across the world, Taiwanese green beauty brand O’right continues to make significant strides in sustainability. This year, O’right made headlines with the opening of its store in Isetan Shinjuku, a leading department store in Japan. Now, the pioneering brand has made its way into Lyko, a Sweden-based beauty and hair care chain that has quickly become the Nordic region’s leading player in the segment. Recently, the green innovator celebrates the Good Design Gold Award (Japan’s Good Design Award is one of the top 4 design awards in the world) honor for its latest innovation – the world’s greenest toothpaste – to offer new green lifestyle solutions worldwide. O’right continues its commitment to doing what’s best for people, the society and earth and calls on businesses and people to follow suit. What started as a small, unknown name in Taiwan has now evolved into a zero carbon beauty brand that is taking the beauty sector by storm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005486/en/
A visionary brand that’s here to stay
O’right and the Swedish beauty retailer Lyko first crossed paths at Cosmoprof Bologna. Founded in the world’s most sustainable country, Lyko partners with brands and stocks products that align with its own values and meets its high standards. O’right has been leading the way to sustainability for years, from its innovative 8 Free standard for creating non-toxic, clean and multi-award-winning range of green products to recently receiving the USDA Certified Biobased Product Label. This year, the company aims to achieve zero carbon (carbon neutrality) for 77 of its products. O’right’s commitment to sustainability is shown not only in its values, but also from product formulations to packaging. The trailblazer demonstrates a positive social and environmental impact and powerful visionary narratives that justify its worth and inspire the Swedish-based chain to wholeheartedly invest in. It’s safe to say that the cosmetic world is excited to watch as the partnership between two companies that share the same values from the East and the West blossoms into something incredible.
Green without borders
Lyko boasts Sweden’s largest e-commerce site with an average monthly traffic count of 4 million visits, along with 37 physical stores in Sweden and Norway. Lyko joins forces with O’right, opening the door for the Taiwanese brand to make its green values and products seen in the Nordic region. O’right green products even made it into the e-commerce platform’s top sellers list. As a green zero carbon brand, O’right believes that the key to making a greater influence in every part of the world is to inspire green living and consumption. When it comes to sustainability, distance and national borders don’t matter.
Does O’right, a small Taiwanese company from the small land of Taiwan, have what it takes to conquer the eco beauty sector of the Nordic region? O’right is determined to show its green value and wow consumers with its holistic green lifestyle solutions and innovative trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005486/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
